Chitosan and silver nanoparticles: promising anti-toxoplasma agents.

[1]  Xing-Quan Zhu,et al.  DNA immunization with eukaryotic initiation factor-2α of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice. , 2013, Vaccine.

[2]  M. Fakhar,et al.  In vitro treatments of Echinococcus granulosus with fungal chitosan, as a novel biomolecule. , 2013, Asian Pacific journal of tropical biomedicine.

[3]  M. Rafailovich,et al.  Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro. , 2013, Experimental parasitology.

[4]  F. Ahmad,et al.  Improved antifilarial activity of ivermectin in chitosan–alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi , 2013, Parasitology Research.

[5]  Cara L. Wilhelm,et al.  TLR-independent neutrophil-derived IFN-γ is important for host resistance to intracellular pathogens , 2013, Proceedings of the National Academy of Sciences.

[6]  Haifang Wang,et al.  Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo. , 2013, Toxicology letters.

[7]  G. Xie,et al.  A novel immunosensor for detecting toxoplasma gondii-specific IgM based on goldmag nanoparticles and graphene sheets. , 2013, Colloids and surfaces. B, Biointerfaces.

[8]  Sabyasachi Das,et al.  Synthesis, characterization of chitosan-tripolyphosphate conjugated chloroquine nanoparticle and its in vivo anti-malarial efficacy against rodent parasite: a dose and duration dependent approach. , 2012, International journal of pharmaceutics.

[9]  Haliza Katas,et al.  Antifungal Activity of Chitosan Nanoparticles and Correlation with Their Physical Properties , 2012, International journal of biomaterials.

[10]  F. Robert-Gangneux,et al.  Epidemiology of and Diagnostic Strategies for Toxoplasmosis , 2012, Clinical Microbiology Reviews.

[11]  Y. Gohar,et al.  Validity of silver, chitosan, and curcumin nanoparticles as anti-Giardia agents , 2012, Parasitology Research.

[12]  Javad Shokri,et al.  Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice , 2011, International journal of nanomedicine.

[13]  S. Jarudilokkul,et al.  Preparation of chitosan nanoparticles for encapsulation and release of protein , 2011 .

[14]  M. Heimesaat,et al.  Immunology of Toxoplasma gondii , 2011, Immunological reviews.

[15]  M. Heimesaat,et al.  SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers , 2011, Journal of drug targeting.

[16]  U. Vogel,et al.  Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate , 2011, Particle and Fibre Toxicology.

[17]  I. Yu,et al.  Subchronic oral toxicity of silver nanoparticles , 2010, Particle and Fibre Toxicology.

[18]  M. Thanou,et al.  Biodegradation, biodistribution and toxicity of chitosan. , 2010, Advanced drug delivery reviews.

[19]  Dakrong Pissuwan,et al.  Destruction and control of Toxoplasma gondii tachyzoites using gold nanosphere/antibody conjugates. , 2009, Small.

[20]  R. Müller,et al.  The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis , 2009, Journal of drug targeting.

[21]  M. Eissa,et al.  Synthesis and evaluation of some pyrimidine analogs against toxoplasmosis , 2008, Medicinal Chemistry Research.

[22]  Dakrong Pissuwan,et al.  A golden bullet? Selective targeting of Toxoplasma gondii tachyzoites using antibody-functionalized gold nanorods. , 2007, Nano letters.

[23]  Kemin Wang,et al.  Preparation and antibacterial activity of Fe3O4@Ag nanoparticles , 2007 .

[24]  L. Garcia Macroscopic and Microscopic Examination of Fecal Specimens , 2007 .

[25]  O. Pardini,et al.  Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. , 2006, International journal of pharmaceutics.

[26]  H. B. Liu,et al.  Biosynthesis and characterization of Ti/Ni bimetallic nanoparticles , 2006 .

[27]  R. Pandey,et al.  Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. , 2006, The Indian journal of chest diseases & allied sciences.

[28]  Tetsuya Osaka,et al.  THE STUDY OF ANTIMICROBIAL ACTIVITY AND PRESERVATIVE EFFECTS OF NANOSILVER INGREDIENT , 2005 .

[29]  C. Roberts,et al.  Triazine Inhibits Toxoplasma gondii Tachyzoites In Vitro and In Vivo , 2005, Antimicrobial Agents and Chemotherapy.

[30]  A. Nikolić,et al.  Effectiveness of spiramycin in murine models of acute and chronic toxoplasmosis. , 2005, International journal of antimicrobial agents.

[31]  Jing-huai Fang,et al.  The study of deposited silver particulate films by simple method for efficient SERS , 2005 .

[32]  M. Kurowski,et al.  Atovaquone Maintenance Therapy Prevents Reactivation of Toxoplasmic Encephalitis in a Murine Model of Reactivated Toxoplasmosis , 2004, Antimicrobial Agents and Chemotherapy.

[33]  D. Buxton,et al.  Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. , 2004, Vaccine.

[34]  J. de Braekeleer,et al.  Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. , 2003, International journal of pharmaceutics.

[35]  Bing Xu,et al.  Presenting Vancomycin on Nanoparticles to Enhance Antimicrobial Activities , 2003 .

[36]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[37]  Helmut Hahn,et al.  Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis , 2001, Antimicrobial Agents and Chemotherapy.

[38]  L. Weiss,et al.  Toxoplasma gondii: from animals to humans. , 2000, International journal for parasitology.

[39]  F. Derouin,et al.  Cotrimoxazole for prenatal treatment of congenital toxoplasmosis? , 2000, Parasitology today.

[40]  K. Ismail,et al.  Novel triazolo[4,3-a]quinazolinone and bis-triazolo[4,3-a:4,3'-c]quinazolines: synthesis and antitoxoplasmosis effect. , 1999, Farmaco.

[41]  D. Mazier,et al.  Encephalitozoon intestinalis: humoral responses in interferon-gamma receptor knockout mice infected with a microsporidium pathogenic in AIDS patients. , 1998, Experimental parasitology.

[42]  B. Luft,et al.  Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice , 1986, Antimicrobial Agents and Chemotherapy.

[43]  T. Asai,et al.  Transmission and scanning electron microscopy of host cell entry by Toxoplasma gondii. , 1977, The American journal of pathology.

[44]  E. R. Dalton Statistics in Small Doses , 1972 .

[45]  W. Castle Statistics in small doses , 1972 .

[46]  C. Betsch,et al.  Scanning-beam electron microscopy of selected microorganisms. , 1970, The Journal of infectious diseases.

[47]  E. De,et al.  Spiramycin therapy of experimental toxoplasmosis in mice , 1958 .